FIELD: medicine; genetic engineering.
SUBSTANCE: invention relates to a method for the expansion of cells modified by genetic engineering methods, which includes one or both of administration of an inhibitor of an immune control point and biopsy of an individual with tumor or malignant tumor. Cells modified by genetic engineering methods were previously administered to the specified individual for the treatment of the specified tumor or malignant tumor, 12 months or less before one or both of administration of the inhibitor of an immune control point and biopsy. Cells modified by genetic engineering methods contain T-cells, and the specified cells modified by genetic engineering methods express a recombinant receptor.
EFFECT: proposed method leads to an increase in the expansion and, in some cases, to more stable and long-lasting response of cells modified by genetic engineering methods after the destruction and/or treatment.
52 cl, 9 dwg, 10 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION OF CONSTRUCTED CELLS FOR ADOPTIVE CELL THERAPY | 2017 |
|
RU2780156C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| METHODS FOR PRODUCTION OF COMPOSITIONS OF GENETICALLY ENGINEERED CELLS AND RELATED COMPOSITIONS | 2018 |
|
RU2790444C2 |
| METHODS AND COMPOSITIONS FOR OBTAINING GENETICALLY ENGINEERED CELLS | 2018 |
|
RU2795454C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
